Counselling the family of a survivor starting hormone replacement — OSCE

A strong candidate frames the conversation around the three questions the parents are really asking — is the cancer back, what will we do, and what will happen — and addresses the fear of recurrence directly before anything else. The slowing growth is explained in plain language as a recognised and treatable consequence of the cranial radiation that cured the tumour, not a sign that the tumour has returned: the radiation that saved his life has slowed the gland that produces the growth signal, so the bones are not growing at the normal rate, and this was an expected and anticipated possibility at the three-year mark. The scheduled magnetic resonance imaging scan is framed as the routine confirmation of stable disease that must precede the growth hormone therapy, not as an investigation driven by a new suspicion of recurrence. [1] [3]

The therapy discussion covers the two hormone problems honestly and in sequence. The low cortisol is addressed first and framed as the more urgent of the two, because cortisol is what the body uses to cope with stress and infection: the boy will take a small daily dose of hydrocortisone to replace what his gland cannot make, and the parents are taught the sick-day rules — doubling or tripling the dose during a fever, and giving the emergency injection if he vomits or becomes unwell — because missing this is the one preventable emergency in his future. The growth hormone therapy is explained as a daily subcutaneous injection at bedtime to mimic the body's natural overnight signal, with the dose adjusted to a blood test (the IGF-1), and the family is reassured that the response is best when treatment is started early and taken consistently. [2]

The outlook is reassuring but honest. Most children respond well in the first year, the aim is to reach an adult height close to the family's genetic potential, and the therapy continues until near-final height with periodic re-testing. The parents are told that the endocrine late effects are lifelong, that further deficiencies may appear over time, and that the long-term follow-up programme will see him annually to screen for them — so the endocrinology team becomes a permanent part of his care alongside the oncology surveillance. The consultation closes by acknowledging the parents' anxiety, normalising the injection burden with the support of the nurse specialist, confirming the written sick-day plan and the emergency injection, and setting a clear follow-up appointment after the magnetic resonance imaging scan. [1] [2]